Close Menu

NEW YORK (GenomeWeb) – Investment bank Piper Jaffray has upgraded its rating on Genomic Health's stock to overweight, maintaining a price target for shares of $72, based on an assessment of the current pace of the company's business ahead of a German reimbursement decision that is expected to finalize today.

In a note to investors, analyst William Quirk said that the company's stock has been off significantly since it announced its Q1 earnings, necessitating the rating upgrade to maintain the existing price target.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Guardian reports that some UK physicians are calling for increased regulation of direct-to-consumer genetic tests.

US tax agency says 23andMe's genetic health test can be claimed as a medical expense for tax purposes, the Wall Street Journal reports.

Two Democratic lawmakers argue at USA Today that independent science is under attack by the Trump Administration.

In PLOS this week: networks of genes co-expressed in depression, role of minichromosome maintenance genes in lung adenocarcinoma, and more.